- Flunoxaprofen USP/EP/BP
-
- $1.10 / 1g
-
2021-06-10
- CAS:66934-18-7
- Min. Order: 1g
- Purity: 99.9%
- Supply Ability: 100 Tons Min
|
| | Flunoxaprofen Basic information |
| Product Name: | Flunoxaprofen | | Synonyms: | Flunoxaprofen;(S)-2-(4-Fluorophenyl)-α-methyl-5-benzoxazoleacetic acid;Priaxim;S-(+)-Flunoxaprofen;Flunoxaprofen USP/EP/BP;5-Benzoxazoleacetic acid, 2-(4-fluorophenyl)-α-methyl-, (αS)- | | CAS: | 66934-18-7 | | MF: | C16H12FNO3 | | MW: | 285.273 | | EINECS: | | | Product Categories: | | | Mol File: | 66934-18-7.mol |  |
| | Flunoxaprofen Chemical Properties |
| Melting point | 162-164° | | alpha | D20 +50° (c = 2% in DMF) | | Boiling point | 419.4±30.0 °C(Predicted) | | density | 1.334±0.06 g/cm3(Predicted) | | pka | 4.36±0.30(Predicted) |
| Toxicity | LD50 orally in mice: ~1200 mg/kg (Dunwell) |
| | Flunoxaprofen Usage And Synthesis |
| Description | Flunoxaprofen is an antiinflammatory related to now withdrawn benoxaprofen, reportedly
useful in the treatment of rheumatoid arthritis, myositis, synovitis and osteoarthritis. Its
major mechanism of action is reported to be lipoxygenase inhibition, thus enabling the
control of inflammation with less severe gastric disturbances. | | Originator | Ravizza (Italy) | | Definition | ChEBI: A monocarboxylic acid that is propionic acid substituted at position 2 by a 2-(4-chlorophenyl)-1,3-benzoxazol-5-yl group (the S-enantiomer). Although it was shown to be effective in treatment of rheumatoid arthritis and osteoarthritis, the
clinical use of flunoxaprofen was discontinued due to possible hepatotoxic side-effects. | | Brand name | Priaxim |
| | Flunoxaprofen Preparation Products And Raw materials |
|